Women with metastatic triple-negative breast cancer respond twice as well to chemotherapy if Cetuximab is added, researchers revealed at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. They said that targeting the epidermal growth factor receptor (EGFR) can double the response rate compared to only cisplatin chemotherapy...
More...
Threaded Mode